Association of busulfan area under the curve with veno-occlusive disease following BMT.
about
Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsGlutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Busulfan in hematopoietic stem cell transplantationPopulation pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseasClinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplantBiomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell TransplantationA simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patientsTherapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipientsVariation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipientsBusulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomesTargeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease.Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care.
P2860
Q28067102-9E86A7C6-DD18-49E3-8B5F-EF94365AC111Q33558113-E2EBAFFD-BDA5-47E8-A773-9091DF2F3755Q33978951-B0EA150F-D25A-4904-8C1F-FDB5C7A74FB7Q34220717-AB557929-EED0-4B7D-A913-AC49F79842EAQ34409335-62C5B505-24C4-4B35-986E-A7378C498399Q34505185-76A21099-DA2E-4E4C-9A64-7F00FC27604DQ34668052-CD14D595-1A57-4147-B84B-66373857E699Q35126138-E9473714-1970-4DBD-A55A-82FEA1993132Q35486314-18B397DB-E3B2-41E7-8DA6-177129666C50Q35770722-1461B167-E40B-41A6-A8A1-11C400AF838FQ35787013-772C2DF9-654D-44C7-92E3-48C7A77597ADQ36055238-E7ECCE1A-2699-456A-BBE4-BAFFFD835282Q36166109-C914C779-AACC-49C2-89DF-1C494F568878Q36703516-C5516C46-1E5D-4AB1-B2B7-D3B27DCF08EBQ36792760-097CBAE5-E85C-4238-9C82-F78DD1D8699EQ36881201-786415BA-606F-471D-94ED-8D943162FCECQ36892839-6771660E-BAB2-49DA-A196-5AB04804FA8EQ37001941-5F9EB3C9-007B-4814-8584-91F02F63823FQ37070285-DD26E342-D33B-4FD4-8226-117B09C9A024Q37224427-36C5881F-D560-4DB3-B781-DF8968FEC65DQ37359565-A73ED418-5724-40A6-9467-9E5FD0BAB33FQ37504482-2DA43E99-FDD8-41D9-834D-B0FEB1564BE7Q37525678-194AD385-56D7-40F5-93FD-E42C0EEB4C5AQ37738997-37AFCA66-20A5-43F1-9A59-054E69EB1685Q38847841-5B50EC20-2389-4A25-AFB5-BA1C23DA789EQ40690518-54E5DF3E-5B34-431A-A113-6713667F4D6CQ41862636-65224FD8-40AB-4C69-8BD2-C99734558C54Q42351682-27048E5B-3132-4536-8361-7139AC6F737EQ47124626-2B389D5F-0158-4806-AFBD-3367F2A16CCDQ50043715-EE03DADC-0403-4021-96C8-AFBDAF508DDBQ52613271-863EA700-EDEF-4E8C-9D1F-701D13FBB4A7Q53108123-D6F544F1-66C3-4A2A-8955-A884928D0DE5
P2860
Association of busulfan area under the curve with veno-occlusive disease following BMT.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Association of busulfan area under the curve with veno-occlusive disease following BMT.
@en
Association of busulfan area under the curve with veno-occlusive disease following BMT.
@nl
type
label
Association of busulfan area under the curve with veno-occlusive disease following BMT.
@en
Association of busulfan area under the curve with veno-occlusive disease following BMT.
@nl
prefLabel
Association of busulfan area under the curve with veno-occlusive disease following BMT.
@en
Association of busulfan area under the curve with veno-occlusive disease following BMT.
@nl
P2093
P1476
Association of busulfan area under the curve with veno-occlusive disease following BMT
@en
P2093
Davidson TG
Gilmore CE
Heffner LT
Hillyer CD
Holland HK
Jerkunica I
P304
P407
P577
1996-02-01T00:00:00Z